Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P6-02-05
Brittany Colosimo, Kevin Weinberger, S. Hasan, Steven Gresswell, Sidney Anderson, R. Wegner, M. Trombetta
{"title":"Abstract P6-02-05: Downstream workup after post-treatment mammography in breast conservation therapy: Is there a significant difference between tomosynthesis and 2-dimensional mammograms?","authors":"Brittany Colosimo, Kevin Weinberger, S. Hasan, Steven Gresswell, Sidney Anderson, R. Wegner, M. Trombetta","doi":"10.1158/1538-7445.SABCS18-P6-02-05","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P6-02-05","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74821445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P3-10-10
J. Edwards, G. Baillie, J. Quinn, R. Monreno, Sourav Banerjee, N. Tomkinson, S. Mackay, L. D. L. Vega
Background Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) belongs to a family of CMGC kinases that function as modulators of different downstream pathways that allow cells to cope with hypoxia, DNA damage and various stress signals. Additionally, DYRK2 has been implicated in various human cancers with both pro- and anti-tumour roles, which are probably cancer type- and cell type-dependent. Furthermore, studies show that DYRK2 is involved in epithelial-mesenchymal transition, hence suggesting a role in tumour metastasis. The current study investigates the prognostic role of DYRK2 in breast cancer and investigates its potential as a novel therapeutic target. Methods Immunohistochemistry was employed to investigate if nuclear expression of DYRK2 was associated with clinical outcome measures in a cohort of 715 patients. Expression was determined using the weighted histoscore method. Antibody specificity was confirmed in paraffin embedded cell pellets +/- DYRK2 silencing. Cell counts in parental and CRISPR-mediated DYRK2 knocked-out MDA-MB-468 and MDA-MB-231 cells (ER, PR, HER2, AR negative) were measured using Alamar Blue; NSGTMmice (n=8) were injected subcutaneously with MDA-MDB-231 with or without DYRK2 depletion to assess tumour growth in vivo. Results In a cohort of 715 patients, median follow-up was 160 months with 155 breast cancer deaths and 135 deaths due to other causes. The majority of patients were over 50 years of age (71%), had ductal carcinoma (88%), tumours 145 were classified as high expression. In the full cohort (p=0.087) and ER negative (p=0.066) cohort DYRK2 was not associated with cancer specific survival. However in TN disease high DYRK2 expression was associated with cancer specific survival (p=0.012, mean survival 145 months versus 107 months). This was potentiated in patients with ER, PR, HER2, AR negative disease (p=0.005, mean survival 166 months versus 100 months) and independent in multivariate analysis with age, histological tumour type, tumour size tumour grad, nodal status, ki67 index, chemotherapy, radiotherapy and recurrence (p=0.13, HR 3.920). Following this observation, patients with ER, AR negative disease were investigated and again high DYRK2 expression was associated with cancer specific survival (p=0.0003, mean survival 163 months versus 86 months) and was independent when combined in multivariate analysis (p=0.001, HR 4.154). To investigate if DYRK2 was a potential target in TN breast cancer, the effect of silencing DYRK2 was investigated. CRISPR-mediated DYRK2 depletion impeded cell proliferation in TN cell-lines and markedly reduced tumour burden in mouse MDA-MDB-231 xenografts (p Conclusions Our studies indicate that DYRK2 is indeed a potential therapeutic target for patients with TN breast cancer or ER, AR negative breast cancer. Citation Format: Edwards J, Baillie G, Quinn J, Monreno R, Banerjee S, Tomkinson N, MacKay S, De La Vega L. DYRK2 is a novel therapeutic target in ER negati
双特异性酪氨酸磷酸化调节激酶2 (DYRK2)属于CMGC激酶家族，作为不同下游途径的调节剂，使细胞能够应对缺氧、DNA损伤和各种应激信号。此外，DYRK2在多种人类癌症中具有促肿瘤和抗肿瘤的作用，这可能是癌症类型和细胞类型依赖的。此外，研究表明DYRK2参与上皮-间质转化，因此提示在肿瘤转移中起作用。目前的研究调查了DYRK2在乳腺癌中的预后作用，并研究了它作为一种新的治疗靶点的潜力。方法采用免疫组织化学方法研究DYRK2的核表达是否与715例患者的临床预后指标相关。采用加权直方图评分法测定表达。在石蜡包埋细胞颗粒+/- DYRK2沉默中证实抗体特异性。使用Alamar Blue检测亲代和crispr介导的DYRK2敲除的MDA-MB-468和MDA-MB-231细胞(ER、PR、HER2、AR阴性)的细胞计数;对NSGTMmice (n=8)皮下注射MDA-MDB-231，同时或不同时去除DYRK2，以评估体内肿瘤的生长情况。结果在715例患者的队列中，中位随访时间为160个月，其中155例乳腺癌死亡，135例因其他原因死亡。大多数患者年龄在50岁以上(71%)，有导管癌(88%)，肿瘤145个被分类为高表达。在完全队列(p=0.087)和ER阴性队列(p=0.066)中，DYRK2与癌症特异性生存无关。然而，在TN疾病中，DYRK2高表达与癌症特异性生存相关(p=0.012，平均生存145个月对107个月)。在ER、PR、HER2、AR阴性疾病患者中(p=0.005，平均生存期166个月对100个月)，且与年龄、组织学肿瘤类型、肿瘤大小、肿瘤等级、淋巴结状态、ki67指数、化疗、放疗和复发无关(p=0.13, HR 3.920)。在此观察之后，对ER、AR阴性疾病患者进行了调查，再次发现高DYRK2表达与癌症特异性生存相关(p=0.0003，平均生存163个月对86个月)，并且在多因素分析中是独立的(p=0.001, HR 4.154)。为了研究DYRK2是否是TN乳腺癌的潜在靶点，我们研究了沉默DYRK2的效果。crispr介导的DYRK2缺失抑制了TN细胞系的细胞增殖，并显著降低了小鼠MDA-MDB-231异种移植物的肿瘤负担(p结论我们的研究表明，DYRK2确实是TN乳腺癌或ER, AR阴性乳腺癌患者的潜在治疗靶点。引用格式:Edwards J, Baillie G, Quinn J, Monreno R, Banerjee S, Tomkinson N, MacKay S, De La Vega L. DYRK2是雌激素受体阴性乳腺癌新的治疗靶点[摘要]。2018年圣安东尼奥乳腺癌研讨会论文集;2018年12月4-8日;费城(PA): AACR;癌症杂志，2019;79(4增刊):P3-10-10。
{"title":"Abstract P3-10-10: DYRK2 is a novel therapeutic target in ER negative breast cancer","authors":"J. Edwards, G. Baillie, J. Quinn, R. Monreno, Sourav Banerjee, N. Tomkinson, S. Mackay, L. D. L. Vega","doi":"10.1158/1538-7445.SABCS18-P3-10-10","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P3-10-10","url":null,"abstract":"Background Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) belongs to a family of CMGC kinases that function as modulators of different downstream pathways that allow cells to cope with hypoxia, DNA damage and various stress signals. Additionally, DYRK2 has been implicated in various human cancers with both pro- and anti-tumour roles, which are probably cancer type- and cell type-dependent. Furthermore, studies show that DYRK2 is involved in epithelial-mesenchymal transition, hence suggesting a role in tumour metastasis. The current study investigates the prognostic role of DYRK2 in breast cancer and investigates its potential as a novel therapeutic target. Methods Immunohistochemistry was employed to investigate if nuclear expression of DYRK2 was associated with clinical outcome measures in a cohort of 715 patients. Expression was determined using the weighted histoscore method. Antibody specificity was confirmed in paraffin embedded cell pellets +/- DYRK2 silencing. Cell counts in parental and CRISPR-mediated DYRK2 knocked-out MDA-MB-468 and MDA-MB-231 cells (ER, PR, HER2, AR negative) were measured using Alamar Blue; NSGTMmice (n=8) were injected subcutaneously with MDA-MDB-231 with or without DYRK2 depletion to assess tumour growth in vivo. Results In a cohort of 715 patients, median follow-up was 160 months with 155 breast cancer deaths and 135 deaths due to other causes. The majority of patients were over 50 years of age (71%), had ductal carcinoma (88%), tumours 145 were classified as high expression. In the full cohort (p=0.087) and ER negative (p=0.066) cohort DYRK2 was not associated with cancer specific survival. However in TN disease high DYRK2 expression was associated with cancer specific survival (p=0.012, mean survival 145 months versus 107 months). This was potentiated in patients with ER, PR, HER2, AR negative disease (p=0.005, mean survival 166 months versus 100 months) and independent in multivariate analysis with age, histological tumour type, tumour size tumour grad, nodal status, ki67 index, chemotherapy, radiotherapy and recurrence (p=0.13, HR 3.920). Following this observation, patients with ER, AR negative disease were investigated and again high DYRK2 expression was associated with cancer specific survival (p=0.0003, mean survival 163 months versus 86 months) and was independent when combined in multivariate analysis (p=0.001, HR 4.154). To investigate if DYRK2 was a potential target in TN breast cancer, the effect of silencing DYRK2 was investigated. CRISPR-mediated DYRK2 depletion impeded cell proliferation in TN cell-lines and markedly reduced tumour burden in mouse MDA-MDB-231 xenografts (p Conclusions Our studies indicate that DYRK2 is indeed a potential therapeutic target for patients with TN breast cancer or ER, AR negative breast cancer. Citation Format: Edwards J, Baillie G, Quinn J, Monreno R, Banerjee S, Tomkinson N, MacKay S, De La Vega L. DYRK2 is a novel therapeutic target in ER negati","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78914621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.sabcs18-p4-10-06
Marcy L. Schaeffer, B. May, A. Cimino-Mathews, Mikiaila M. Orellana, Michelle S. McCullough, B. Hogan, D. Armstrong, K. Visvanathan
Background: Clinical/epidemiologic observational studies frequently rely on participants9 recall for information about breast procedures. However, there is limited data on the accuracy of self-reported breast procedures. To address this knowledge gap and inform future study design and collection and interpretation of similar data, we investigated the impact of type, diagnosis, age, time, and other patient characteristics on the accuracy of self-report in a prospective cohort. Methods: All benign breast biopsies, lumpectomies, and mastectomies for breast cancer treatment among women enrolled in the BOSS Cohort, a prospective study of women and men with a familial risk of breast/ovarian cancer, were identified. Study staff obtained pathology reports for 93% of women from self-reported breast procedure locations. For this analysis, we focused on 577 women who had at least one ascertained pathology report, and who self-reported at least one breast procedure at baseline. We estimated the percentage of self-reports (95% confidence interval (CI)) with matching pathology report within 6 months (+/- 6 months), and agreement between self-reported procedures and pathology-confirmed diagnoses (normal/benign vs. atypical hyperplasia vs. LCIS, and DCIS vs. invasive cancer) with the Kappa statistic. We also examined predictors of an accurate biopsy self-report, including age at baseline, personal and family history of breast cancer, educational attainment, and time between biopsy and baseline, using logistic regression models. Results: At baseline, 158 women reported having at least one benign biopsy, 193 women reported having a lumpectomy for cancer treatment, and 174 women reported having a mastectomy for cancer treatment. The median time between biopsy, lumpectomy, mastectomy, and baseline was 9 years, 2 years, and 2 years, respectively. Fifty-seven percent (95% CI: 49-64.5%) of benign biopsy self-reports, 90.7% (95% CI: 85.6-94.1%) of lumpectomy self-reports, and 85.1% (95% CI: 78.9-89.7%) of mastectomy self-reports had a matching pathology report within 6 months. Further diagnostic agreement was moderate for biopsies, lumpectomies, and mastectomies with Kappa statistics of 0.65, 0.66, 0.65, respectively. Age at baseline (p-interaction =0.01) and time (p-interaction = 0.03) were independent and joint predictors of accurate biopsy self-reports. Women less than 49 years old had the largest reduction in odds of having an accurate self-report (26%) for every additional year between biopsy and baseline [adjusted odds ratio = 0.74 (95% CI: 0.63-0.88)]. Similarly, women with a biopsy within 4 years prior to baseline had a 10% reduction in the odds of having an accurate self-report with increasing age [adjusted odds ratio = 0.9 (95% CI: 0.84-0.97)]. Conclusions: In this highly-educated cohort, the overall accuracy of self-report of benign biopsies was only modest, and the accuracy of self-report of lumpectomies and mastectomies was lower than expected. This study s
背景:临床/流行病学观察性研究经常依赖于参与者对乳房手术信息的回忆。然而，关于自我报告乳房手术的准确性的数据有限。为了解决这一知识差距，并为未来的研究设计、收集和解释类似数据提供信息，我们在前瞻性队列中调查了类型、诊断、年龄、时间和其他患者特征对自我报告准确性的影响。方法:在BOSS队列(一项对具有乳腺癌/卵巢癌家族风险的女性和男性进行的前瞻性研究)中，对所有参与乳腺癌治疗的女性进行了良性乳腺活检、乳房肿瘤切除术和乳房切除术。研究人员从自我报告的乳房手术地点获得了93%的妇女的病理报告。在这项分析中，我们重点研究了577名至少有一份明确的病理报告，并在基线时自我报告至少一次乳房手术的妇女。我们估计了6个月内(+/- 6个月)自我报告与病理报告相匹配的百分比(95%置信区间(CI))，以及自我报告的程序与病理确诊诊断(正常/良性vs.非典型增生vs. LCIS, DCIS vs.浸润性癌)之间的一致性与Kappa统计。我们还检查了准确活检自我报告的预测因素，包括基线年龄、个人和家族史、教育程度、活检和基线之间的时间，使用逻辑回归模型。结果:在基线时，158名妇女报告至少有一次良性活检，193名妇女报告为癌症治疗而进行乳房肿瘤切除术，174名妇女报告为癌症治疗而进行乳房切除术。活检、乳房肿瘤切除术、乳房切除术和基线之间的中位时间分别为9年、2年和2年。57% (95% CI: 49-64.5%)的良性活检自我报告，90.7% (95% CI: 85.6-94.1%)的乳房肿瘤切除术自我报告，85.1% (95% CI: 78.9-89.7%)的乳房切除术自我报告在6个月内有匹配的病理报告。活检、肿瘤和乳房切除术的进一步诊断一致性中等，Kappa统计值分别为0.65、0.66和0.65。基线年龄(p-交互作用=0.01)和时间(p-交互作用= 0.03)是准确活检自我报告的独立和联合预测因子。在活检和基线之间每增加一年，49岁以下的女性获得准确自我报告的几率降低最大(26%)[校正优势比= 0.74 (95% CI: 0.63-0.88)]。同样，在基线前4年内进行活检的女性，随着年龄的增长，获得准确自我报告的几率降低10%[校正优势比= 0.9 (95% CI: 0.84-0.97)]。结论:在这个高学历的队列中，良性活检自我报告的总体准确性仅为中等，肿瘤和乳房切除术自我报告的准确性低于预期。本研究表明，基线年龄和手术与基线之间的时间是自我报告准确性的重要预测因素，在使用自我报告信息时应予以考虑。此外，在可能的情况下，应优先考虑乳房手术数据的前瞻性收集。引用格式:Schaeffer ML, May B, Cimino-Mathews A, Orellana M, McCullough M, Hogan B, Armstrong D, Visvanathan K.影响乳腺癌妇女自我报告乳房手术准确性的因素[摘要]。2018年圣安东尼奥乳腺癌研讨会论文集;2018年12月4-8日;费城(PA): AACR;癌症杂志，2019;79(4增刊):P4-10-06。
{"title":"Abstract P4-10-06: Factors impacting the accuracy of self-reported breast procedures among women with and without breast cancer","authors":"Marcy L. Schaeffer, B. May, A. Cimino-Mathews, Mikiaila M. Orellana, Michelle S. McCullough, B. Hogan, D. Armstrong, K. Visvanathan","doi":"10.1158/1538-7445.sabcs18-p4-10-06","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs18-p4-10-06","url":null,"abstract":"Background: Clinical/epidemiologic observational studies frequently rely on participants9 recall for information about breast procedures. However, there is limited data on the accuracy of self-reported breast procedures. To address this knowledge gap and inform future study design and collection and interpretation of similar data, we investigated the impact of type, diagnosis, age, time, and other patient characteristics on the accuracy of self-report in a prospective cohort. Methods: All benign breast biopsies, lumpectomies, and mastectomies for breast cancer treatment among women enrolled in the BOSS Cohort, a prospective study of women and men with a familial risk of breast/ovarian cancer, were identified. Study staff obtained pathology reports for 93% of women from self-reported breast procedure locations. For this analysis, we focused on 577 women who had at least one ascertained pathology report, and who self-reported at least one breast procedure at baseline. We estimated the percentage of self-reports (95% confidence interval (CI)) with matching pathology report within 6 months (+/- 6 months), and agreement between self-reported procedures and pathology-confirmed diagnoses (normal/benign vs. atypical hyperplasia vs. LCIS, and DCIS vs. invasive cancer) with the Kappa statistic. We also examined predictors of an accurate biopsy self-report, including age at baseline, personal and family history of breast cancer, educational attainment, and time between biopsy and baseline, using logistic regression models. Results: At baseline, 158 women reported having at least one benign biopsy, 193 women reported having a lumpectomy for cancer treatment, and 174 women reported having a mastectomy for cancer treatment. The median time between biopsy, lumpectomy, mastectomy, and baseline was 9 years, 2 years, and 2 years, respectively. Fifty-seven percent (95% CI: 49-64.5%) of benign biopsy self-reports, 90.7% (95% CI: 85.6-94.1%) of lumpectomy self-reports, and 85.1% (95% CI: 78.9-89.7%) of mastectomy self-reports had a matching pathology report within 6 months. Further diagnostic agreement was moderate for biopsies, lumpectomies, and mastectomies with Kappa statistics of 0.65, 0.66, 0.65, respectively. Age at baseline (p-interaction =0.01) and time (p-interaction = 0.03) were independent and joint predictors of accurate biopsy self-reports. Women less than 49 years old had the largest reduction in odds of having an accurate self-report (26%) for every additional year between biopsy and baseline [adjusted odds ratio = 0.74 (95% CI: 0.63-0.88)]. Similarly, women with a biopsy within 4 years prior to baseline had a 10% reduction in the odds of having an accurate self-report with increasing age [adjusted odds ratio = 0.9 (95% CI: 0.84-0.97)]. Conclusions: In this highly-educated cohort, the overall accuracy of self-report of benign biopsies was only modest, and the accuracy of self-report of lumpectomies and mastectomies was lower than expected. This study s","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78385012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.sabcs18-p4-14-04
Hyung-Jin Kim, W. Noh, S. Nam, B-W. Park, Eddie Lee, S. Im, Ys Jung, Jh Yoon, S. Kang, K. park, S. Lee, J. Jung, Min-Kyung Lee, Sohyung Cho, S. Kim, H. Kim, S. Han, W. Han, M. Hur, S.H. Ahn
{"title":"Abstract P4-14-04: Time course changes in serum FSH, estradiol, and menstruation restoration in premenopausal patients with breast cancer taking adjuvant tamoxifen after completing chemotherapy: A report from the ASTRRA study","authors":"Hyung-Jin Kim, W. Noh, S. Nam, B-W. Park, Eddie Lee, S. Im, Ys Jung, Jh Yoon, S. Kang, K. park, S. Lee, J. Jung, Min-Kyung Lee, Sohyung Cho, S. Kim, H. Kim, S. Han, W. Han, M. Hur, S.H. Ahn","doi":"10.1158/1538-7445.sabcs18-p4-14-04","DOIUrl":"https://doi.org/10.1158/1538-7445.sabcs18-p4-14-04","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78433273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P5-04-09
H. Mo, Xin Wang, Z. Qian, Binghe Xu
This abstract was not presented at the conference. Citation Format: Mo H, Wang X, Qian Z, Xu B, Ma F. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-09.
{"title":"Abstract P5-04-09: Not presented","authors":"H. Mo, Xin Wang, Z. Qian, Binghe Xu","doi":"10.1158/1538-7445.SABCS18-P5-04-09","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P5-04-09","url":null,"abstract":"This abstract was not presented at the conference. Citation Format: Mo H, Wang X, Qian Z, Xu B, Ma F. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-09.","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75932714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P1-12-01
V. Bjelic-Radisic, A. Bottomley, F. Cardoso, D. Cameron, E. Brain, K. Kuljanić, R. D. de Costa, T. Conroy, V. Deville, E. Inwald, S. Serpentini, M. Pinto, E. Bleiker, J. Arrares, F. Duhoux, J. Weiss, O. Morag, G. Lindviksmoen Astrup, K. Tomaszweksi, G. Velikova, K. Pogoda, E. Nagele, B. Bliem, P. Sinai, M. Sprangers, N. Aaronson, E. Greimel
{"title":"Abstract P1-12-01: Withdrawn","authors":"V. Bjelic-Radisic, A. Bottomley, F. Cardoso, D. Cameron, E. Brain, K. Kuljanić, R. D. de Costa, T. Conroy, V. Deville, E. Inwald, S. Serpentini, M. Pinto, E. Bleiker, J. Arrares, F. Duhoux, J. Weiss, O. Morag, G. Lindviksmoen Astrup, K. Tomaszweksi, G. Velikova, K. Pogoda, E. Nagele, B. Bliem, P. Sinai, M. Sprangers, N. Aaronson, E. Greimel","doi":"10.1158/1538-7445.SABCS18-P1-12-01","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P1-12-01","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75077965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P2-07-10
H-B. Lee, Ke Kim, Yw Ju, Jg Jung, H. Ryu, Sb Lee, J. Lee, H. Lee, Mk Kim, Sung Min Kwon, J. Kim, Chulhong Kim, H. Moon, D. Noh, S.H. Ahn, I. Park, S. Kim, Sungsoo Yoon, A. Kim, W. Han
{"title":"Abstract P2-07-10: Not presented","authors":"H-B. Lee, Ke Kim, Yw Ju, Jg Jung, H. Ryu, Sb Lee, J. Lee, H. Lee, Mk Kim, Sung Min Kwon, J. Kim, Chulhong Kim, H. Moon, D. Noh, S.H. Ahn, I. Park, S. Kim, Sungsoo Yoon, A. Kim, W. Han","doi":"10.1158/1538-7445.SABCS18-P2-07-10","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P2-07-10","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77653119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P2-03-12
Ramesh Choudhari, Alana L Harrison, C. Carrillo, S. Gadad
{"title":"Abstract P2-03-12: Role of nucleus-specific intergenic long noncoding RNA-1476 in estrogen-dependent transcription in cancer","authors":"Ramesh Choudhari, Alana L Harrison, C. Carrillo, S. Gadad","doi":"10.1158/1538-7445.SABCS18-P2-03-12","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P2-03-12","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77672930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P3-03-34
Y. Uemoto, N. Kondo, Yumi Wanifuchi-Endo, T. Hisada, S. Nishikawa, Y. Katagiri, Hiroyuki Kato, Satoru Takahashi, T. Toyama
{"title":"Abstract P3-03-34: Sentinel lymph node biopsy is unnecessary in ductal carcinomain situpatients diagnosed by biopsy","authors":"Y. Uemoto, N. Kondo, Yumi Wanifuchi-Endo, T. Hisada, S. Nishikawa, Y. Katagiri, Hiroyuki Kato, Satoru Takahashi, T. Toyama","doi":"10.1158/1538-7445.SABCS18-P3-03-34","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P3-03-34","url":null,"abstract":"","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77684670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-15DOI: 10.1158/1538-7445.SABCS18-P4-14-12
N. Williams, Joseph Liu, J. Stephens, M. Palettas, H. Boutrid, S. Sardesai, R. Reinbolt, D. Stover, J. Vandeusen, A. Noonan, R. Wesolowski, M. Lustberg, B. Ramaswamy
Background:Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancers and is clinically and biologically distinct from invasive ductal carcinoma (IDC). Despite that, women with early stage ILC are often treated similarly to IDC. However, several retrospective studies suggest that patients (pts) with ILC may not derive survival benefit from the addition of chemotherapy to endocrine therapy relative to pts with IDC. The purpose of our study was to compare outcomes of pts with ILC treated with chemotherapy with those who received endocrine monotherapy. Methods: A retrospective review of pts with ILC or pleomorphic lobular carcinoma treated at the Ohio State University James Cancer Center from 2004-2014 was performed. Clinico-pathologic characteristics, treatment summary and clinical outcomes were collected. Distant disease-free survival (DDFS) was defined as time from diagnosis to the first distant metastases or death and overall survival (OS) was the time from diagnosis to death or last known follow up. DDFS and OS curves were created using Kaplan-Meier methods and compared using log-rank tests. Cox proportional hazard models were used to calculate univariate and multi variable hazard ratios (HR) for OS and DDFS. Results: We identified 379 pts with early stage ILC (stage I: 43% (162/379), stage II: 34% (127/379), stage III: 22% (84/379), unknown: 1% (6/379)). The majority of pts were post-menopausal (79%), Caucasian (92%) and ER+/PR+ (87%) and HER2 negative (96%). One hundred seventy six pts (46%) received chemotherapy and 189 (50%) pts received endocrine therapy alone. Pts who received chemotherapy had stage II or III disease, positive lymph nodes and grade 2 or 3 tumors; while pts who received endocrine monotherapy had stage I disease, negative lymph nodes and grade 1 or 2 tumors. We found a 51% decrease in chemotherapy (from 63% to 31%) and an increase in endocrine monotherapy use (from 34% to 65%) between 2004-2010 and 2011-2014. One hundred thirty two pts were evaluated with Oncotype DX, of which 76% (100/132) were node negative with the majority having a low recurrence score (low: 64%; intermediate: 33%; high: 3%). The use of Oncotype DX increased from 21.1% in 2004-2010 to 47.9% in 2011-2014. We found that 112 of 149 pts with at least 5 years follow up (75.2%) successfully completed five or more years of endocrine therapy. Univariate cox models showed worse DDFS HRs for type of therapy and node status (HR: 2.36, p=0.005, HR: 4.16, p Conclusion: We found no difference in DDFS between endocrine monotherapy and chemotherapy after adjusting for age, grade, and nodal involvement in pts with early stage ILC. This supports the hypothesis that ILC may not derive a significant benefit from the addition of chemotherapy. We need more prospective clinical trials considering histology to better understand how best to treat ILC. Citation Format: Williams N, Liu J, Stephens J, Palettas M, Boutrid H, Sardesai S, Reinbolt R, Stover D, VanD
背景:浸润性小叶癌(ILC)占所有乳腺癌的15%，在临床和生物学上不同于浸润性导管癌(IDC)。尽管如此，早期ILC的女性通常与IDC的治疗方法相似。然而，一些回顾性研究表明，相对于IDC患者，ILC患者可能无法从在内分泌治疗中增加化疗中获得生存益处。本研究的目的是比较接受化疗的ILC患者与接受内分泌单一疗法的患者的预后。方法:回顾性分析2004-2014年在俄亥俄州立大学詹姆斯癌症中心治疗的ILC或多形性小叶癌患者。收集临床病理特征、治疗总结及临床结果。远端无病生存期(DDFS)定义为从诊断到首次远处转移或死亡的时间，总生存期(OS)定义为从诊断到死亡或最后一次已知随访的时间。采用Kaplan-Meier法绘制DDFS和OS曲线，并用log-rank检验进行比较。采用Cox比例风险模型计算OS和DDFS的单因素和多因素风险比(HR)。结果:我们确定了379例早期ILC患者(I期:43% (162/379)，II期:34% (127/379)，III期:22%(84/379)，未知:1%(6/379))。大多数患者为绝经后(79%)、白种人(92%)、ER+/PR+(87%)和HER2阴性(96%)。176例(46%)接受化疗，189例(50%)单独接受内分泌治疗。接受化疗的患者为II期或III期疾病、淋巴结阳性和2级或3级肿瘤;而接受内分泌单一疗法的患者为I期疾病、淋巴结阴性和1级或2级肿瘤。我们发现，2004-2010年至2011-2014年间，化疗减少了51%(从63%降至31%)，而内分泌单一疗法的使用增加了(从34%降至65%)。132名患者接受Oncotype DX评估，其中76%(100/132)为淋巴结阴性，大多数复发评分较低(低:64%;中级:33%;高:3%)。Oncotype DX的使用率从2004-2010年的21.1%上升到2011-2014年的47.9%。我们发现，随访至少5年的149名患者中，有112名(75.2%)成功完成了5年或更长时间的内分泌治疗。单因素cox模型显示，治疗类型和淋巴结状态的DDFS HRs更差(HR: 2.36, p=0.005, HR: 4.16, p)。结论:在调整年龄、分级和早期ILC患者的淋巴结累及后，我们发现内分泌单药治疗和化疗的DDFS无差异。这支持了ILC可能不会从增加化疗中获得显着益处的假设。我们需要更多考虑组织学的前瞻性临床试验，以更好地了解如何最好地治疗ILC。引用格式:Williams N, Liu J, Stephens J, Palettas M, Boutrid H, Sardesai S, Reinbolt R, Stover D, VanDeusen J, Noonan A, Wesolowski R, Lustberg M, Ramaswamy B.激素受体阳性侵袭性小叶癌的预后[摘要]。2018年圣安东尼奥乳腺癌研讨会论文集;2018年12月4-8日;费城(PA): AACR;癌症杂志，2019;79(4增刊):P4-14-12。
{"title":"Abstract P4-14-12: Outcomes in hormone receptor positive, invasive lobular cancer in the era of endocrine monotherapy","authors":"N. Williams, Joseph Liu, J. Stephens, M. Palettas, H. Boutrid, S. Sardesai, R. Reinbolt, D. Stover, J. Vandeusen, A. Noonan, R. Wesolowski, M. Lustberg, B. Ramaswamy","doi":"10.1158/1538-7445.SABCS18-P4-14-12","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-P4-14-12","url":null,"abstract":"Background:Invasive lobular carcinoma (ILC) accounts for up to 15% of all breast cancers and is clinically and biologically distinct from invasive ductal carcinoma (IDC). Despite that, women with early stage ILC are often treated similarly to IDC. However, several retrospective studies suggest that patients (pts) with ILC may not derive survival benefit from the addition of chemotherapy to endocrine therapy relative to pts with IDC. The purpose of our study was to compare outcomes of pts with ILC treated with chemotherapy with those who received endocrine monotherapy. Methods: A retrospective review of pts with ILC or pleomorphic lobular carcinoma treated at the Ohio State University James Cancer Center from 2004-2014 was performed. Clinico-pathologic characteristics, treatment summary and clinical outcomes were collected. Distant disease-free survival (DDFS) was defined as time from diagnosis to the first distant metastases or death and overall survival (OS) was the time from diagnosis to death or last known follow up. DDFS and OS curves were created using Kaplan-Meier methods and compared using log-rank tests. Cox proportional hazard models were used to calculate univariate and multi variable hazard ratios (HR) for OS and DDFS. Results: We identified 379 pts with early stage ILC (stage I: 43% (162/379), stage II: 34% (127/379), stage III: 22% (84/379), unknown: 1% (6/379)). The majority of pts were post-menopausal (79%), Caucasian (92%) and ER+/PR+ (87%) and HER2 negative (96%). One hundred seventy six pts (46%) received chemotherapy and 189 (50%) pts received endocrine therapy alone. Pts who received chemotherapy had stage II or III disease, positive lymph nodes and grade 2 or 3 tumors; while pts who received endocrine monotherapy had stage I disease, negative lymph nodes and grade 1 or 2 tumors. We found a 51% decrease in chemotherapy (from 63% to 31%) and an increase in endocrine monotherapy use (from 34% to 65%) between 2004-2010 and 2011-2014. One hundred thirty two pts were evaluated with Oncotype DX, of which 76% (100/132) were node negative with the majority having a low recurrence score (low: 64%; intermediate: 33%; high: 3%). The use of Oncotype DX increased from 21.1% in 2004-2010 to 47.9% in 2011-2014. We found that 112 of 149 pts with at least 5 years follow up (75.2%) successfully completed five or more years of endocrine therapy. Univariate cox models showed worse DDFS HRs for type of therapy and node status (HR: 2.36, p=0.005, HR: 4.16, p Conclusion: We found no difference in DDFS between endocrine monotherapy and chemotherapy after adjusting for age, grade, and nodal involvement in pts with early stage ILC. This supports the hypothesis that ILC may not derive a significant benefit from the addition of chemotherapy. We need more prospective clinical trials considering histology to better understand how best to treat ILC. Citation Format: Williams N, Liu J, Stephens J, Palettas M, Boutrid H, Sardesai S, Reinbolt R, Stover D, VanD","PeriodicalId":20307,"journal":{"name":"Poster Session Abstracts","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77901404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：